Compare
Verrica Pharmaceuticals Inc. vs Sunshine Biopharma Inc. vs BGM Group Ltd. vs Zomedica Corp.
| Latest fiscal year | Verrica Pharmaceuticals Inc. VRCA | Sunshine Biopharma Inc. SBFM | BGM Group Ltd. BGM | Zomedica Corp. ZOMDF |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-09-30 | 2025-12-31 |
| Revenue | $35.58M | $36.31M | $37.92M | $32.03M |
| Revenue growth (YoY) | +370.2% | +4.1% | +51.1% | +17.4% |
| Gross margin | n/a | 33.8% | 16.6% | 67.7% |
| Operating margin | -34.2% | -17.2% | -33.2% | -263.4% |
| Net margin | -50.3% | -16.5% | -52.6% | -255.6% |
| Net income | -$17.89M | -$5.98M | -$19.94M | -$81.86M |
| EPS (Diluted) | -$1.68 | n/a | -$0.18 | -$0.08 |
| Operating cash flow | -$17.63M | -$5.33M | -$2.37M | -$17.65M |
| Free cash flow | -$17.63M | -$5.51M | -$3.94M | -$18.22M |
| Cash & equivalents | $30.15M | n/a | $9.82M | $9.02M |
| Total assets | $47.13M | $30.08M | $433.81M | $127.04M |
| Total liabilities | $22.39M | $7.04M | $41.92M | $11.64M |
| Shareholders' equity | $24.74M | $23.04M | $391.90M | $115.40M |
| Return on year-end equity | -72.3% | -25.9% | -5.1% | -70.9% |
| Shares outstanding | 17.18M | 4.91M | 200.62M | 979.95M |
Revenue, most recent five fiscal years
| Fiscal year | Verrica Pharmaceuticals Inc. | Sunshine Biopharma Inc. | BGM Group Ltd. | Zomedica Corp. |
|---|---|---|---|---|
| Latest | $35.58M Ended 2025-12-31 | $36.31M Ended 2025-12-31 | $37.92M Ended 2025-09-30 | $32.03M Ended 2025-12-31 |
| 1 year earlier | $7.57M Ended 2024-12-31 | $34.87M Ended 2024-12-31 | $25.10M Ended 2024-09-30 | $27.29M Ended 2024-12-31 |
| 2 years earlier | $5.12M Ended 2023-12-31 | $24.09M Ended 2023-12-31 | $46.47M Ended 2023-09-30 | $25.19M Ended 2023-12-31 |
| 3 years earlier | $9.03M Ended 2022-12-31 | $4.35M Ended 2022-12-31 | $64.86M Ended 2022-09-30 | $18.93M Ended 2022-12-31 |
| 4 years earlier | $12.00M Ended 2021-12-31 | $228.4K Ended 2021-12-31 | $57.10M Ended 2021-09-30 | $4.13M Ended 2021-12-31 |